Literature DB >> 26228529

Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro.

Haiping He1, Tokiko Nagamura-Inoue, Atsuko Takahashi, Yuka Mori, Yuki Yamamoto, Takahisa Shimazu, Hajime Tsunoda, Arinobu Tojo.   

Abstract

Recent studies have reported that mesenchymal stromal cells (MSCs) migrate to areas of inflammation and suppress adverse immune reactions. Bone marrow (BM)-derived MSCs have been successfully used in patients with acute graft versus host disease (GVHD), but the harvesting of BM carries certain risks for the donor. To circumvent these, we obtained MSCs from Wharton's jelly (WJ) derived from umbilical cord and investigated their potential for immunosuppression. In a mixed lymphocyte reaction (MLR), responder T cell proliferation triggered by allogeneic dendritic cells was inhibited efficiently by WJ-MSCs derived from the same donor of responder cells or those from a third party donor. These inhibitory effects were reversed in a dose-dependent manner in the presence of 1-methyl-DL-tryptophan, an inhibitor of the soluble factor indoleamine 2, 3-dioxygenase (IDO). Immunosuppression by WJ-MSCs was also attenuated by blocking cell-cell contact between WJ-MSCs and responder T cells using a Transwell chamber. Moreover, IDO gene expression was induced in both WJ- and BM-MSCs by inflammatory cytokine IFN-γ, but HLA-DR was expressed in BM-MSCs and not in WJ-MSCs upon stimulation by a relatively low concentration of IFN-γ. These results indicate that WJ-MSCs exert their immunosuppressive effects by cell-cell contact with activated T cells and in part through IDO, and suggest the need for cells rather than soluble factors secreted from MSCs to achieve immunosuppressive therapy in severe cases of GVHD.

Entities:  

Mesh:

Year:  2015        PMID: 26228529     DOI: 10.1007/s12185-015-1844-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

1.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

Authors:  E M Horwitz; K Le Blanc; M Dominici; I Mueller; I Slaper-Cortenbach; F C Marini; R J Deans; D S Krause; A Keating
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

2.  Stage-specific embryonic antigen 4 in Wharton's jelly-derived mesenchymal stem cells is not a marker for proliferation and multipotency.

Authors:  Haiping He; Tokiko Nagamura-Inoue; Hajime Tsunoda; Miki Yuzawa; Yuki Yamamoto; Pariko Yorozu; Hideki Agata; Arinobu Tojo
Journal:  Tissue Eng Part A       Date:  2014-03-14       Impact factor: 3.845

3.  Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton's jelly explants of human umbilical cord.

Authors:  Ikuo Ishige; Tokiko Nagamura-Inoue; Masaki J Honda; Ratanakanit Harnprasopwat; Michiko Kido; Mitsuhiro Sugimoto; Hiromitsu Nakauchi; Arinobu Tojo
Journal:  Int J Hematol       Date:  2009-08-06       Impact factor: 2.490

4.  Characteristic change and loss of in vivo osteogenic abilities of human bone marrow stromal cells during passage.

Authors:  Hideki Agata; Izumi Asahina; Nobukazu Watanabe; Yumiko Ishii; Noriyuki Kubo; Satoshi Ohshima; Mika Yamazaki; Arinobu Tojo; Hideaki Kagami
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

Review 5.  Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration.

Authors:  Jyoti A Kode; Shayanti Mukherjee; Mugdha V Joglekar; Anandwardhan A Hardikar
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

Review 6.  Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine?

Authors:  M E Bernardo; D Pagliara; F Locatelli
Journal:  Bone Marrow Transplant       Date:  2011-04-11       Impact factor: 5.483

7.  CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells.

Authors:  Ding Wang; Ke Chen; Wei Ting Du; Zhi-Bo Han; He Ren; Ying Chi; Shao Guang Yang; Francis Bayard; Delin Zhu; Zhong Chao Han
Journal:  Exp Cell Res       Date:  2010-04-24       Impact factor: 3.905

8.  Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells.

Authors:  Parul Trivedi; Peiman Hematti
Journal:  Exp Hematol       Date:  2008-01-07       Impact factor: 3.084

9.  IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.

Authors:  David Polchert; Justin Sobinsky; Gw Douglas; Martha Kidd; Ada Moadsiri; Eduardo Reina; Kristyn Genrich; Swati Mehrotra; Suman Setty; Brett Smith; Amelia Bartholomew
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

10.  Human umbilical cord provides a significant source of unexpanded mesenchymal stromal cells.

Authors:  Akie Kikuchi-Taura; Akihiko Taguchi; Takayoshi Kanda; Takayuki Inoue; Yukiko Kasahara; Haruka Hirose; Iori Sato; Tomohiro Matsuyama; Takayuki Nakagomi; Kenichi Yamahara; David Stern; Hiroyasu Ogawa; Toshihiro Soma
Journal:  Cytotherapy       Date:  2012-02-20       Impact factor: 5.414

View more
  6 in total

1.  Activation of the Extracellular Signal-Regulated Kinase Signaling Is Critical for Human Umbilical Cord Mesenchymal Stem Cell Osteogenic Differentiation.

Authors:  Chen-Shuang Li; Zhong Zheng; Xiao-Xia Su; Fei Wang; Michelle Ling; Min Zou; Hong Zhou
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

Review 2.  Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation.

Authors:  Cécile Pochon; Anne-Béatrice Notarantonio; Caroline Laroye; Loic Reppel; Danièle Bensoussan; Allan Bertrand; Marie-Thérèse Rubio; Maud D'Aveni
Journal:  J Cell Mol Med       Date:  2022-01-28       Impact factor: 5.310

3.  HLA-G and CD152 Expression Levels Encourage the Use of Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells as an Alternative for Immunosuppressive Therapy.

Authors:  Bernardo Zoehler; Letícia Fracaro; Lidiane Maria Boldrini-Leite; José Samuel da Silva; Paul J Travers; Paulo Roberto Slud Brofman; Maria da Graça Bicalho; Alexandra Cristina Senegaglia
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

4.  Umbilical Cord-Derived Mesenchymal Stromal Cells Contribute to Neuroprotection in Neonatal Cortical Neurons Damaged by Oxygen-Glucose Deprivation.

Authors:  Takeo Mukai; Arinobu Tojo; Tokiko Nagamura-Inoue
Journal:  Front Neurol       Date:  2018-06-15       Impact factor: 4.003

5.  Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly.

Authors:  Kuo-An Chu; Shih-Yao Wang; Chang-Ching Yeh; Tz-Win Fu; Yu-Yi Fu; Tsui-Ling Ko; Mei-Miao Chiu; Tien-Hua Chen; Pei-Jiun Tsai; Yu-Show Fu
Journal:  Theranostics       Date:  2019-09-17       Impact factor: 11.556

6.  Locally Delivered Umbilical Cord Mesenchymal Stromal Cells Reduce Chronic Inflammation in Long-Term Nonhealing Wounds: A Randomized Study.

Authors:  Yulia Suzdaltseva; Sergey Zhidkih; Sergey L Kiselev; Victor Stupin
Journal:  Stem Cells Int       Date:  2020-02-14       Impact factor: 5.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.